<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37978296</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>17</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>"The burden of post-acute COVID-19 symptoms in a multinational network cohort analysis".</ArticleTitle><Pagination><StartPage>7449</StartPage><MedlinePgn>7449</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7449</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-42726-0</ELocationID><Abstract><AbstractText>Persistent symptoms following the acute phase of COVID-19 present a major burden to both the affected and the wider community. We conducted a cohort study including over 856,840 first COVID-19 cases, 72,422 re-infections and more than 3.1 million first negative-test controls from primary care electronic health records from Spain and the UK (Sept 2020 to Jan 2022 (UK)/March 2022 (Spain)). We characterised post-acute COVID-19 symptoms and identified key symptoms associated with persistent disease. We estimated incidence rates of persisting symptoms in the general population and among COVID-19 patients over time. Subsequently, we investigated which WHO-listed symptoms were particularly differential by comparing their frequency in COVID-19 cases vs. matched test-negative controls. Lastly, we compared persistent symptoms after first infections vs. reinfections.Our study shows that the proportion of COVID-19 cases affected by persistent post-acute COVID-19 symptoms declined over the study period. Risk for altered smell/taste was consistently higher in patients with COVID-19 vs test-negative controls. Persistent symptoms were more common after reinfection than following a first infection. More research is needed into the definition of long COVID, and the effect of interventions to minimise the risk and impact of persistent symptoms.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, CSM, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Roel</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>I Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Aut&#xf2;noma de Barcelona, Bellaterra (Cerdanyola del Vall&#xe8;s), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinh</LastName><ForeName>Nhung T H</ForeName><Initials>NTH</Initials><Identifier Source="ORCID">0000-0003-2794-5322</Identifier><AffiliationInfo><Affiliation>PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercad&#xe9;-Besora</LastName><ForeName>N&#xfa;ria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>I Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0388-3403</Identifier><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, CSM, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateu</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita contra les Infeccions, Badalona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>Roger</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6553-691X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Lluita contra les Infeccions, Badalona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>irsiCaixa AIDS Research Institute, Badalona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>I Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, CSM, NDORMS, University of Oxford, Oxford, United Kingdom. daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands. daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catal&#xe0;</LastName><ForeName>Mart&#xed;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, CSM, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf6;dicke</LastName><ForeName>Annika M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, CSM, NDORMS, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000084063" MajorTopicYN="N">Reinfection</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>D.P.A.&#x2019;s department has received grant/s from Amgen, Chiesi&#x2013;Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA&#x2019;s department. LM reports grants from Grifols, speaker fees from AstraZeneca and Gilead and participation in Advisory Boards for Gilead. NT is supported by the Norwegian Research Council (grant No. 288696) and has received internationalisation support from UiO: Life Science and travel grants from the Norwegian Research Council. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>18</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>18</Day><Hour>1</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37978296</ArticleId><ArticleId IdType="pmc">PMC10656441</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-42726-0</ArticleId><ArticleId IdType="pii">10.1038/s41467-023-42726-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Office for National Statistics. Coronavirus (COVID-19) Infection Survey, UK: 11 November 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/11november2022 (accessed 01 December 2022).</Citation></Reference><Reference><Citation>Mahase, E. Covid-19: what do we know about &#x201c;long covid&#x201d;? Br. Med. J.370, m2815 (2020). (published online first 16 July 2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Perego, E. et al. Why the Patient-Made Term &#x2018;Long Covid&#x2019; is needed. Wellcome Open Res.10.12688/wellcomeopenres.16307.1 (2020).</Citation></Reference><Reference><Citation>Greenhalgh T, et al. Long covid-an update for primary care. Br. Med. J. 2022;378:e072117. doi: 10.1136/bmj-2022-072117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072117</ArticleId><ArticleId IdType="pubmed">36137612</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen, M. et al. Characterising long COVID: a living systematic review. BMJ Glob. Health10.1136/bmjgh-2021-005427 (2021) (published online first 29 Sep 2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, et al. Long covid-mechanisms, risk factors, and management. Br. Med. J. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus 6 October 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Reese, J. T. et al. Generalizable long COVID subtypes: findings from the NIH N3C and RECOVER programs. medRxiv10.1101/2022.05.24.22275398 (2022) (published online first 7 June 2022).</Citation></Reference><Reference><Citation>Kenny G, et al. Identification of distinct long COVID clinical phenotypes through cluster analysis of self-reported symptoms. Open Forum Infect. Dis. 2022;9:ofac060. doi: 10.1093/ofid/ofac060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac060</ArticleId><ArticleId IdType="pmc">PMC8900926</ArticleId><ArticleId IdType="pubmed">35265728</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. J. Am. Med. Assoc. 328,1604&#x2013;1615 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer RR, et al. Characterizing long COVID: deep phenotype of a complex condition. EBioMedicine. 2021;74:103722. doi: 10.1016/j.ebiom.2021.103722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103722</ArticleId><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: an overview. Diabetes Metab. Syndr. 2021;15:869&#x2013;875. doi: 10.1016/j.dsx.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentilotti E, et al. Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort. EClinicalMedicine. 2023;62:102&#x2013;107. doi: 10.1016/j.eclinm.2023.102107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102107</ArticleId><ArticleId IdType="pmc">PMC10466236</ArticleId><ArticleId IdType="pubmed">37654668</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian. A. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med.28, 1706&#x2013;1714 (2022). (published online first: 26 July 2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat. Commun. 2022;13:1957. doi: 10.1038/s41467-022-29521-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29521-z</ArticleId><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency. The effectiveness of vaccination against long COVID: a rapid evidence briefing 2022 (accessed February 2022).</Citation></Reference><Reference><Citation>Magnusson K, et al. Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants. Nat. Commun. 2022;13:7363. doi: 10.1038/s41467-022-35240-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35240-2</ArticleId><ArticleId IdType="pmc">PMC9709355</ArticleId><ArticleId IdType="pubmed">36450749</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford N., et al. Long COVID and Significant Activity Limitation Among Adults, by Age&#x2014;United States, June 1&#x2013;13, 2022, to June 7&#x2013;19, 2023. US Department of Health and Human Services, Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report; 72 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10415000</ArticleId><ArticleId IdType="pubmed">37561665</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoy, J. et al. Prevalence of Symptoms &#x2264;12 Months After Acute Illness, by COVID-19 Testing Status Among Adults&#x2014;United States, December 2020&#x2013;March 2023. US Department of Health and Human Services, Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report; 72 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10415002</ArticleId><ArticleId IdType="pubmed">37561663</ArticleId></ArticleIdList></Reference><Reference><Citation>Horberg, M. A. et al. Post-acute sequelae of SARS-CoV-2 with clinical condition definitions and comparison in a matched cohort. Nat. Commun.10.1038/s41467-022-33573-6 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556630</ArticleId><ArticleId IdType="pubmed">36224218</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe, B., Xie, Y. &amp; Al-Aly, Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat. Med.28, 2398&#x2013;2405 (2022). (published online first 11 Nov 2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosworth M., Shenhuy B., Ayoubkhani D. New-onset, self-reported long COVID after coronavirus (COVID-19) reinfection in the UK: 23 February 2023. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/newonsetselfreportedlongcovidaftercoronaviruscovid19reinfectionintheuk/23february2023 (accessed 23 February 2023).</Citation></Reference><Reference><Citation>Recalde M, et al. Data resource profile: the information system for research in primary care (SIDIAP) Int. J. Epidemiol. 2022;51:e324&#x2013;e336. doi: 10.1093/ije/dyac068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyac068</ArticleId><ArticleId IdType="pmc">PMC9749711</ArticleId><ArticleId IdType="pubmed">35415748</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney LL, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. doi: 10.1016/j.eclinm.2022.101762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int. J. Epidemiol. 2019;48:1740&#x2013;40g. doi: 10.1093/ije/dyz034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyz034</ArticleId><ArticleId IdType="pmc">PMC6929522</ArticleId><ArticleId IdType="pubmed">30859197</ArticleId></ArticleIdList></Reference><Reference><Citation>CPRD. Release Notes: CPRD Aurum June 2021 10.48329/pyc2-we97 (2021).</Citation></Reference><Reference><Citation>Burn, E. et al. Establishing and characterising large COVID-19 cohorts after mapping the Information System for Research in Primary Care in Catalonia to the OMOP Common Data Model. medRxiv10.1101/2021.11.23.21266734 (2021).</Citation></Reference><Reference><Citation>The Book of OHDSI. Chapter 4 The Common Data Model. https://ohdsi.github.io/TheBookOfOhdsi/CommonDataModel.html (2022).</Citation></Reference><Reference><Citation>Rao, G. et al. CohortDiagnostics: Diagnostics for OHDSI Cohorts. https://ohdsi.github.io/CohortDiagnostics/2022 (2022).</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), and Royal College of General Practitioners (RCGP). COVID-19 rapid guideline: managing the long term effects of COVID-19 2022. https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742 (accessed 3 November 2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>